Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of The Private Securities Litigation Reform Act of 1995.

JP Morgan Healthcare Conference January

2019 Targeting Disease at the Nuclear Pore Exhibit 99.1

Forward-looking Statements and Other

Important Information This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those

regarding the therapeutic potential of and potential clinical development plans and commercialization for Karyopharm's drug candidates, including the timing of initiation of certain trials, of the reporting of data from such trials, of the

submissions to regulatory authorities and of potential commercial launches, the potential availability of accelerated approval pathways, the potential size of the markets for multiple myeloma drugs and multiple myeloma drugs for treatment of

patients with relapsed multiple myeloma and Karyopharm's strategic and financial plans and expectations as well as financial projections for Karyopharm. Such statements are subject to numerous important factors, risks and uncertainties that

may cause actual events or results to differ materially from Karyopharm's current expectations. For example, there can be no guarantee that regulators will agree that selinexor qualifies for accelerated approval in the U.S. or conditional

approval in the E.U. as a result of the data from the STORM study in patients with penta-refractory myeloma or SADAL study in patients with relapsed/refractory DLBCL or that any of Karyopharm's drug candidates, including selinexor (KPT-330)

and eltanexor (KPT-8602), Karyopharm's second generation SINE compound, or KPT-9274, Karyopharm's first-in-class oral dual inhibitor of PAK4 and NAMPT, or any other drug candidate Karyopharm is developing, will successfully complete

necessary preclinical and clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in Karyopharm's drug candidate portfolio

will result in stock price appreciation. In addition, even if Karyopharm receives marketing approval for selinexor or another drug candidate, there can be no assurance that Karyopharm will be able to successfully commercialize that drug candidate.

Management's expectations and, therefore, any forward-looking statements in this presentation could also be affected by risks and uncertainties relating to a number of other factors, many of which are beyond Karyopharm's control,

including the following: Karyopharm's results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the FDA

and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical studies; the ability of Karyopharm or its third party collaborators or

successors in interest to fully perform their respective obligations under the applicable agreement and the potential future financial implications of such agreement; unplanned cash requirements and expenditures; development of drug candidates by

Karyopharm's competitors for diseases for which Karyopharm is currently developing its drug candidates; that the markets for multiple myeloma drugs will grow as predicted; and Karyopharm's ability to obtain, maintain and enforce patent

and other intellectual property protection for any drug candidates it is developing. These and other risks, including those which may impact management's expectations, are described in greater detail under the heading "Risk Factors" in

Karyopharm's Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, which is on file with the SEC, and in subsequent filings filed by Karyopharm with the SEC. Any forward-looking statements contained in this presentation are

for informational purposes only and speak only as of the date hereof. Other than as is required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or

otherwise. Karyopharm's website is http://www.karyopharm.com. Karyopharm regularly uses its website to post information regarding its business, drug development programs and governance. Karyopharm encourages investors to use

www.karyopharm.com, particularly the information in the section entitled "Investors," as a source of information about Karyopharm. References to www.karyopharm.com in this presentation are not intended to, nor shall they be deemed to,

incorporate information on www.karyopharm.com into this presentation by reference. Unless otherwise noted, this presentation contains data that are interim and unaudited based on site reports. In addition, data included in this presentation have not

been updated and are as of the cutoff date for the applicable medical conference presentation. Unless otherwise noted, all reference to market sizes are based on reports from Global Data or Karyopharm internal estimates. Selinexor, eltanexor,

KPT-9274 and verdinexor are investigational drugs that have not been approved by the FDA or any other regulatory agency. The safety and efficacy of these drugs has not been established by any agency. 2019 Karyopharm Therapeutics Inc.

2019 Karyopharm Therapeutics Inc.

Agenda Overview of Karyopharm Review of recently presented clinical data Summary of selinexor tolerability profile Potential commercial opportunity Additional pipeline activities Financial update and expected near-term milestones

Founded 10 years ago by team of highly

successful cancer drug developers; Initial public offering in 2013 Novel, focused technology approach with potential for broad clinical applicability Industry leader in targeting nuclear export dysregulation as a mechanism to treat cancer All

programs developed in-house; Pivotal clinical data presented in 2018 in multiple myeloma and diffuse large B-cell lymphoma (DLBCL) First NDA with request for accelerated approval in penta-refractory multiple myeloma under Priority Review with FDA

(April 6, 2019 PDUFA date) and MAA submission for Europe expected in January 2019; 2nd NDA in relapsed or refractory DLBCL expected in 2019 Ongoing clinical development for lead candidate and next-generation programs in earlier lines of treatment,

in combination trials, and in additional tumor types across both hematologic and solid tumor malignancies Numerous data read-outs and potential key milestones expected over the next 12-24 months Karyopharm at a Glance 2019 Karyopharm

Progress and Plans to Become an

Oncology Leader 2019 Karyopharm Therapeutics Inc. 2013-2018 Supported the growing body of clinical data for our lead investigational compound 2019 Goals Transition to a commercial oncology company 2020+ Goals Expand commercial position, drive

broader utilization and advance follow-on pipeline Advanced lead compound with a novel mechanism of action with broad anti-tumor activity Designed and executed a robust clinical development program with a focus in 4 core cancer types Initiated first

set of regulatory filings in preparation for initial commercial launch Initial commercial launch into U.S. market Submit regulatory filings in initial myeloma indication, globally Initiate first set of regulatory filings in DLBCL Expand commercial

sales in core markets Initiate regulatory filings and commercial sales into earlier lines of myeloma treatment Advance regulatory filings in solid tumors Advance follow-on pipeline programs

Increases nuclear levels and activation

of tumor suppressor proteins Traps oncoprotein mRNA in the nucleus leading to reduced oncoprotein levels Retains activated glucocorticoid receptor in the nucleus Selinexor/SINE Mechanism of Action: Inhibition of XPO11-4 2019 Karyopharm

Therapeutics Inc. Inhibition of XPO1 impacts tumor cells via 3 core mechanisms 1 Gupta A, et al. Therapeutic targeting of nuclear export inhibition in lung cancer. J Thorac Oncol. 2017;12(9):1446-1450. 2 Sun Q, et al. Inhibiting cancer cell hallmark

features through nuclear export inhibition. Signal Transduct Target Ther. 2016;1:16010. 3 Gandhi UH, et al. Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(5):335-345. 4

Gravina GL, et al. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol. 2014;7:85. Selinexor

All Oral Pipeline COMMERCIAL RIGHTS

Japan* Relapsed/refractory | BOSTON Relapsed/refractory | STOMP Penta-refractory | STORM 1 Oral selinexor, Velcade (bortezomib) and dexamethasone vs. Velcade and dexamethasone 2 Oral selinexor + dexamethasone 3 Oral selinexor and dexamethasone

+ Revlimid (lenalidomide), Pomalyst (pomalidomide), Velcade, Kyprolis (carfilzomib) or Darzalex (daratumumab) 4 Investigator-sponsored randomized Phase III trial 2019 Karyopharm Therapeutics Inc. AREA OF THERAPY

PRECLINICAL PHASE I PHASE II PHASE III HEMATOLOGIC MALIGNANCIES Multiple Myeloma SELINEXOR + VELCADE1 SELINEXOR2 SELINEXOR + BACKBONE THERAPIES3 Diffuse Large B-cell Lymphoma | SADAL SELINEXOR SOLID TUMOR MALIGNANCIES Liposarcoma | SEAL SELINEXOR

Endometrial Cancer | SIENDO4 SELINEXOR Glioblastoma | KING SELINEXOR ADDITIONAL ONCOLOGY PROGRAMS MDS, CRC, PrC ELTANEXOR Solid Tumors & Lymphoma KPT-9274 OTHER INDICATIONS Lymphoma in Companion Animals VERDINEXOR Relapsed/refractory | BOSTON

Relapsed/refractory and front-line | STOMP Penta-refractory | STORM *Territories: Japan, S. Korea, Taiwan, Hong Kong, and ASEAN countries. ** Antengene licensed rights to selinexor and eltanexor in China and Macau. *** Antengene licensed rights to

KPT-9274 and verdinexor in mainland China, Macau, Taiwan, Hong Kong, South Korea, and the ASEAN countries. **** Anivive holds exclusive worldwide rights to research, develop and commercialize verdinexor only for the treatment of cancer in companion

animals **** Oral SINE compound and XPO1 inhibitor KPT-350 acquired by Biogen for treatment of certain neurological and neurodegenerative conditions, including ALS, in Jan 2018 China** China*** Granted Priority Review by FDA with PDUFA Date of April

6, 2019 Granted Fast Track designation

Selinexor Clinical Data Update Multiple

Myeloma Diffuse Large-B Cell Lymphoma (DLBCL)

Planned Selinexor Development Strategy

in Multiple Myeloma 2019 Karyopharm Therapeutics Inc. Phase 2b STORM study1 addressing patients with penta-refractory2 myeloma Disease refractory to PIs, IMiDs and Darzalex Highest unmet medical need in multiple myeloma 1 Evaluating

selinexor with low-dose dexamethasone. 2 Patients who have previously received two PIs, Velcade (bortezomib) and Kyprolis (carfilzomib), and two IMiDs, Revlimid (lenalidomide) and Pomalyst (pomalidomide), and the anti-CD38

monoclonal antibody Darzalex (daratumumab), and their disease is refractory to at least one PI, at least one IMiD, and Darzalex , and their most recent therapy. Pivotal Phase 3 BOSTON study addressing patients with relapsed or refractory

disease following 1-3 prior lines of therapy Selinexor combined with once-weekly Velcade and low-dose dexamethasone Phase 1b/2 STOMP as a potential backbone therapy in combination with standard approved therapies Selinexor and low-dose

dexamethasone combined with Revlimid , Pomalyst , Velcade , Kyprolis or Darzalex Future Phase 2/3 studies in combination for labeling

Single-arm clinical trial evaluating

selinexor in combination with low-dose dexamethasone in patients2 with penta-refractory3 myeloma STORM1: A Phase 2b Study In Refractory Myeloma 1 Selinexor Treatment of Refractory Myeloma 2 Median 7 prior regimens 3 Patients who have

previously received two PIs, Velcade (bortezomib) and Kyprolis (carfilzomib), and two IMiDs, Revlimid (lenalidomide) and Pomalyst (pomalidomide), and the anti-CD38 monoclonal antibody Darzalex (daratumumab), and their

disease is refractory to at least one PI, at least one IMiD, and Darzalex , and their most recent therapy. 2019 Karyopharm Therapeutics Inc. Selinexor received Fast Track designation and Priority Review from the FDA for this indication

with PDUFA date of April 6, 2019 MAA expected to be filed in Europe in January 2019

STORM: A Phase 2b Study In

Refractory Myeloma1,2 Safety: As anticipated, the most common non-hematologic AEs were fatigue, nausea, reduced appetite, and weight loss; primarily low grade and manageable with standard supportive care and/or dose modification The most common

hematologic AEs were Grade 3 cytopenias and were generally not associated with clinical sequelae No significant major organ toxicities were observed; low bleeding rates and low infection rates OVERALL RESPONSE RATE1 26.2% 2019

Karyopharm Therapeutics Inc. INCLUDING: 2 sCRs (w/MRD-) 6 VGPRs 24 PRs 1 As confirmed by an Independent Review Committee. 2 Chari A, et al. ASH 2018 Abstract 598. Patients had been treated with a median of 7 prior regimens prior to selinexor

Duration of response: 4.4 months1 Responses were typically rapid in onset (~4 weeks) 68% of patients were confirmed to be refractory to all five of the standard of care myeloma drugs: Revlimid , Velcade , Pomalyst , Kyprolis ,

and Darzalex Overall SURVIVAL BY GROUP 8.6 months 1.7 months 15.6 months Penta-refractory (n=122)

Ongoing randomized, open-label

clinical trial evaluating once weekly selinexor and Velcade (bortezomib) plus low-dose dex versus standard twice-weekly Velcade plus low-dose dex in patients with relapsed or refractory MM, who have had 1-3 prior lines of therapy

BOSTON1: A Phase 3 Study as 2nd Line+ Treatment in Myeloma 1 Bortezomib, Selinexor and dexamethasone 2 Pts must have achieved PR, and completed proteasome inhibitor therapy at least 6 months prior. 3 Pending PFS events 2019 Karyopharm

Therapeutics Inc. Enrollment now completed with top-line data expected by end of 20193

STOMP1: A Phase 1b/2 Study in

Myeloma Ongoing multi-arm clinical trial evaluating selinexor and low-dose dex in combination with several currently marketed "backbone" therapies2 in patients with relapsed or refractory MM 1 Selinexor and Backbone Treatments of

Multiple Myeloma Patients; dosing regimens represent recommended Phase 2 dose (RP2D) in RRMM for SRd, SVd and SDd. RP2D has not been determined for other study arms. 2 Revlimid , Pomalyst , Velcade , Kyprolis or Darzalex

2019 Karyopharm Therapeutics Inc. SRd SEL:60mg QW REV:25mg QD DEX:40mg QW SPd SEL:60 or 80mg QW POM: 2-4mg QD DEX: 40mg QW SVd SEL:100mg QW VEL:1.3mg/m2 SC QW DEX:40mg QW or 20mg BIW Same regimen as in the BOSTON Study SKd SEL:80 or 100mg

QW KYP:56 or 70 mg/m2 IV QW DEX:40 mg QW SDd SEL:100mg QW DARZ:16mg/kg IV QW DEX:40mg QW Continued data read-out at future medical meetings in 2019 Based on positive results of this combination in the relapsed setting, Karyopharm initiated a new,

front-line arm in June 2018 Revlimid Combination Pomalyst Combination Velcade Combination Kyprolis Combination Darzalex Combination

2019 Karyopharm Therapeutics

Inc. 1 Selinexor and Backbone Treatments of Multiple Myeloma Patients. 2 Bahlis NJ, et al. Blood 2018. 3 Gasparetto C, et al. ASH 2018. Abstract 599. 4 Patient population eligible for Phase 3 BOSTON study. 5 Dimopoulos MA et al., Lancet 2016. 6

Lonial et al., Lancet 2016. 7 Five of six had prior Velcade exposure. 8 Revlimid , Pomalyst , Velcade , Kyprolis or Darzalex . Provides strong rationale for further clinical investigation of selinexor in combination with

standard, approved therapies8 Safety: Predictable and manageable tolerability profile; results consistent with those reported from other selinexor studies Most common Grade 1/2 AEs were constitutional symptoms (e.g. nausea, fatigue, anorexia) Most

common Grade 3/4 AEs were cytopenias (e.g. thrombocytopenia, neutropenia, anemia) In the selinexor + Velcade+ dex arm (SVd), peripheral neuropathy across all patients was Grade 1/2 and limited to six patients (14%)7 Selinexor + Darzalex + dex

(SDd)3 (n=28 Most Triple/Quad Refractory) Overall Response Rate In combination with an anti-CD38 mAb Selinexor + Velcade + dex (SVd)2 (n=19 "BOSTON" Type Patients) Overall Response Rate In combination with a proteasome inhibitor

PFS (Months) 5 n=24 4 4 n=19 n=18 6 5 STOMP1: A Phase 1b/2 Study in Myeloma Note: The STORM study does not include any arms studying current myeloma backbone therapies without the combination of selinexor. The purpose of displaying the

"Benchmark" data above for Velcade and Darzalex is to highlight that the clinical results from STORM reported to date strongly support ongoing / additional clinical investigation of selinexor in combination regimens

2019 Karyopharm Therapeutics

Inc. 1 Selinexor and Backbone Treatments of Multiple Myeloma Patients. 2 White D, et al. ASH 2017. Abstract 1861. 3 Chen C, et al. ASH 2018. Abstract 1993. 4 Stewart et al. NEJM 2015. 5 Pomalyst Package Insert. 6 Revlimid , Pomalyst ,

Velcade , Kyprolis or Darzalex . Safety: Predictable and manageable tolerability profile; results consistent with those reported from other selinexor studies Most common Grade 1/2 AEs were constitutional events (e.g. nausea, fatigue,

anorexia) Most common Grade 3/4 AEs were cytopenias (e.g. thrombocytopenia, neutropenia, anemia) Exploring frontline setting: Initiated new all oral arm evaluating selinexor + Revlimid + dex in newly diagnosed patients Selinexor +

Pomalyst + dex (SPd)3 (n=34) Selinexor + Revlimid + dex (SRd)2 (n=16 2nd Line) In combination with immunomodulatory drugs 4 5 n=12 Overall Response Rate Overall Response Rate PFS (Months) n=26 n=26 5 STOMP1: A Phase 1b/2 Study in

Myeloma Provides strong rationale for further clinical investigation of selinexor in combination with standard, approved therapies8 Note: The STORM study does not include any arms studying current myeloma backbone therapies without the combination

of selinexor. The purpose of displaying the "Benchmark" data above for Revlimid and Pomalyst is to highlight that the clinical results from STORM reported to date strongly support ongoing / additional clinical investigation of selinexor

in combination regimens

SADAL1: A Phase 2b Study In DLBCL

Ongoing open-label clinical trial evaluating selinexor in patients with relapsed or refractory ( 3rd line) DLBCL; Approximately 50% of patients with GCB-DLBCL 1 Selinexor Against Diffuse Aggressive Lymphoma 2019 Karyopharm Therapeutics

Inc. Enrollment completed and top-line data reported at ASH 2018 Fast Track designation granted by FDA N 127 selinexor twice weekly (4 week cycle) 60 mg Oral Selinexor Relapsed or Refractory or Transformed DLBCL For patients who have received

two-to-five prior therapies, who are not currently eligible for hematopoietic stem cell transplantation Includes patients with GCB and non-GCB subtypes